The Conversation (0)
Zero Candida Technologies Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Zero Candida Technologies
Investor Insight
Zero Candida’s innovative technology poised to be a game-changer for women’s health presents a compelling investment case to gain exposure to the rapidly expanding fem-tech market.
Overview
Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. Zero Candida offers an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva.
Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida addresses the significant unmet needs of the women’s health market. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.
The fem-tech market is rapidly expanding, projected to reach nearly US$30 billion by 2032. Candidiasis represents a multi-billion-dollar market, with recurrence rates creating sustained demand for effective solutions. Zero Candida’s technology provides a scalable and adaptable platform that addresses both immediate treatment needs and long-term prevention.
Zero Candida is on track to complete clinical trials and file for FDA approval in 2025. The company is listed on the TSXV and the Frankfurt Stock Exchange, expanding its market presence in North America and Europe. With its innovative technology, Zero Candida is well-positioned to set new standards in women’s health management.
Company Highlights
- Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
- Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
- Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
- Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
- The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
- The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.
Key Technology
Zero Candida has developed a groundbreaking solution for vulvovaginal candidiasis (VVC), commonly known as yeast infections. Their SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief
At the core of Zero Candida device use blue light therapy technology. The device employs blue light therapy at a 405 nm wavelength, which has shown remarkable efficacy in targeting Candida fungus. Clinical studies report a 99.99 percent success rate in fungal eradication within three hours of application.
Resembling a tampon for ease of use, the device incorporates temperature, pH, and image sensors. These work with an algorithm to assess the vaginal epithelium, allowing for personalized treatment. The integrated sensors enable the device to monitor treatment progress and signal when optimal vaginal conditions are restored.
Zero Candida's device is designed for convenient at-home use. It features Wi-Fi connectivity, enabling remote consultations and real-time monitoring of treatment progress.
The SMART diagnostic and therapeutic device offers a modular, scalable platform. Beyond candidiasis, the technology has potential applications in other fungal infections and personalized women's health management solutions.
Zero Candida has achieved recent key milestones, including:
- Completed proof-of-concept studies, demonstrating near-complete fungal eradication.
- Raised US$1.6 million in funding, enabling clinical trials and regulatory filings.
- Patent granted in South Africa, with additional filings in the U.S. and EU underway.
- Established partnerships with hospitals and medical experts across Europe and Israel for preclinical validation.
Leadership Team
Eli Ben Haroosh - CEO & Founder
Eli Ben Haroosh is a seasoned entrepreneur with extensive experience in global business operations. Previously, he served as president of the Israeli stock-exchange company Vonetize, and vice-president and CEO of Premier – Dead Sea, managing sales across 74 countries with nearly 1,000 sales points. He also holds leadership roles in multiple companies, including Mariana, focusing on cannabis research and development.
Dr. Asher Holzer - Director & Founder
Dr. Asher Holzer is a highly accomplished entrepreneur with over 30 years of experience in senior management within the medical equipment sector. He has founded and led several companies, including UroGen, InspireMD, BioSig and TheraCoat, some of which were listed on NASDAQ. Holzer holds a doctorate in nuclear physics from the Hebrew University.
Ehud Davidson - Chairman of the Board
Ehud Davidson brings extensive healthcare management expertise as the CEO of Clalit, Israel's largest health maintenance organization, holding 52 percent market share. He successfully led nationwide initiatives, including COVID-19 vaccination campaigns, and oversaw the treatment of the majority of Israeli patients across community and hospital settings.
Dr. Irene Zeitoun - COO & Chief Research Officer
Dr. Irene Zeitoun has over 20 years of managerial experience in biotech and pharmaceutical ventures. She has held key roles, including WW marketing director at Mindset BioPharmaceuticals, director of R&D at Ester Neurosciences, and project manager for the Israeli National Tissue Bank. Zeitoun’s expertise spans business development, operations and commercialization in the healthcare sector.
Asnat Walfisch - Clinical Board Chair
Asnat Walfisch is a distinguished medical professional with a prolific academic and clinical career. She has authored over 150 scientific publications in gynecology and fetal-maternal medicine, and previously served as the Head of Obstetrics and Gynecology at Hadassah Mt. Scopus. She is currently the head of the Helen Schneider Women’s Hospital at Rabin Medical Center.
Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis
Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. The company developed an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.
Zero Candida is on track to complete clinical trials and file for FDA approval in 2024 with its innovative technology.
Zero Candida's SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief
Company Highlights
- Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
- Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
- Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
- Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
- The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
- The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.
This Zero Candida profile is part of a paid investor education campaign.*
Click here to connect with Zero Candida (TSXV:CZT) to receive an Investor Presentation
Syntheia
Investor Insight
Syntheia’s innovative conversational AI solution is transforming the face of customer engagement for the B2B market. Backed by a stable financial foundation, Syntheia is well-placed to execute its growth strategy, offering investors a compelling opportunity.
Overview
Syntheia (CSE:SYAI) has rapidly emerged as an innovative player in the expanding conversational AI platform-as-a-service market.
In an industry poised to transform customer engagement, Syntheia addresses the complex needs of modern communication through cutting-edge AI solutions. Designed to emulate human-like conversations over phone and digital channels, Syntheia’s platform targets both large enterprises and small-to-medium businesses, which often struggle with customer support inefficiencies and high employee turnover in customer-facing roles. Syntheia’s focus on language processing, tonality, sentiment analysis, and conversational behavior makes its offerings distinctive, providing customers an experience that moves closer to natural human interaction than traditional chatbot solutions.
At the core of Syntheia’s strategy is an innovative approach to AI-driven customer service solutions, a sector experiencing explosive growth. The global conversational AI market, valued at $9.9 billion in 2023, is anticipated to reach a staggering $32.62 billion by 2030. With a projected compound annual growth rate of 21.5 percent, the demand for AI solutions that can handle customer inquiries seamlessly is clear. Factors fueling this market growth include the rising demand for customer-centric interactions, the need for operational efficiency, and cost reductions that companies can realize by automating and enhancing their customer support processes. Syntheia is well-positioned within this trend, providing businesses with tools that reduce onboarding costs, language barriers and other operational challenges while enhancing engagement.
Syntheia is listed on the Canadian Securities Exchange under the ticker symbol SYAI, and its stock is closely held, with a tight float that allows for controlled expansion of shares. Financially, the company is in a solid position with $2 million in cash and no debt, and maintains a well-structured capitalization profile that includes options and warrants. This stable financial foundation provides Syntheia with the means to execute its growth strategy while maintaining flexibility to adapt to market shifts.
Company Highlights
- Syntheia is a conversational AI solution delivering AI-driven, human-like customer service for enterprises and SMBs.
- The AssistantNLP Platform offers 24/7/365 multilingual support, accessible globally.
- Syntheia operates on a freemium revenue model, with scalable plans catering to varied business sizes and needs.
- The conversational AI market is expected to reach $32.62 billion by 2030, with Syntheia well-positioned to capitalize on this growth.
- Syntheia’s algorithms have achieved an 84 percent success rate in data collection and 98 percent in outreach programs, highlighting exceptional efficiency.
- Financially stable, Syntheia has $2 million in cash, no debt and trades on the Canadian Securities Exchange.
Key Technology
Syntheia is a front-runner in conversational AI, employing natural language processing (NLP) algorithms that are continually refined for accuracy and contextual understanding. The platform’s advanced NLP technology, bolstered by proprietary algorithms, enables it to understand and respond to various conversational cues, including tone, sentiment, semantics, and even idiomatic expressions. These sophisticated capabilities make interactions feel more fluid, accurate and responsive, which is particularly advantageous in sectors like healthcare, finance and customer service, where nuanced communication is essential. In fact, Syntheia’s algorithms exhibit impressive efficacy rates, achieving an 84 percent success rate in data collection and a 98 percent success rate in outreach initiatives, demonstrating the system’s effectiveness in real-world applications.
One of the most compelling aspects of Syntheia’s solution is its proprietary AssistantNLP platform, which offers 24/7/365 conversational AI service. The AssistantNLP platform is designed to handle high volumes of customer queries in multiple languages and across industries, ensuring a scalable, reliable and flexible solution for diverse customer needs. Syntheia’s platform is also highly accessible, structured around a freemium revenue model that allows businesses to try the service at no cost and then upgrade based on usage and additional features. The freemium model’s flexibility is essential in broadening Syntheia’s customer base by reducing the initial financial commitment for prospective clients and encouraging growth from smaller firms to larger enterprise accounts.
Management Team
Tony Di Benedetto – Chairman, Chief Executive Officer
Tony Di Benedetto has nearly 20 years of IT entrepreneurship, mergers and acquisitions, and capital markets experience. As a seasoned technology business leader, he has successfully built and brought multiple tech businesses to market.
Richard Buzbuzian – President
Richard Buzbuzian is a capital markets executive with over 25 years of investment experience in Canada and Europe, and operates a family office with an investment portfolio of public and pre-IPO companies. Buzbuzian holds a degree from the University of Toronto.
Paul Di Benedetto – Chief Technology Officer
Paul Di Benedetto is a technology visionary with expertise in diverse innovative technologies, including blockchain and AI. He is responsible for overseeing the ongoing development of patent-approved technology at work from Syntheia.
Veronique Laberge – Chief Financial Officer
Veronique Laberge is a chartered professional accountant and holds the title of auditor. With more than 17 years of experience in professional practice, she specializes in certification mandates and general accounting, and acts as a consultant for public and private companies.
Emilio Iantorno – VP of Product & Experience Strategy
Emilio Iantorno, a 20-year design veteran, specializes in crafting engaging product experiences for diverse audiences and industries. Emilio leads the Syntheia design process, effectively harnessing the best technology to tackle business challenges.
Tech 5: AI Takes Center Stage at CES, NVIDIA Unveils Cosmos Platform
1. AI takes center stage at CES
Unsurprisingly, CES underscored the growing influence of artificial intelligence (AI) across the tech landscape, with AI chips for PCs, new electric vehicles and the influence of robotics on the workforce taking center stage.
AI was prominent, featured in everything from appliances to pets. Following substantial investment, companies are under pressure to demonstrate the value and justify the cost of AI integration in their products.
As mentioned, tech stocks rose on Monday as the event began, with chipmakers like NVIDIA (NASDAQ:NVDA), Broadcom (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (AMD) (NASDAQ:AMD) and Taiwan Semiconductor Manufacturing Company (NYSE:TSM) leading the surge.
NVIDIA, whose CEO Jensen Huang gave the keynote address at CES, was a key focus.
Following the company's weaker-than-expected revenue outlook in November, investment interest in AI has been dispersing to include companies such as Broadcom and Marvell Technology (NASDAQ:MRVL), whose share prices increased in the fourth quarter of 2024 while NVIDIA's remained relatively flat.
Broadcom, NVIDIA and Marvell Technology performance, Q4 2024.
Chart via Google Finance.
After a product reveal, NVIDIA saw its share price fall 8.5 percent to US$140.01 on Tuesday (January 7), its largest intraday drop since October 15. Chief among the AI bellwether’s long list of new products are the GeForce RTX 50 series GPUs, built on the Blackwell architecture. The flagship RTX 5090 for demanding workloads will be available this month for US$1,999, while the RTX 5070, a more budget-friendly version, will arrive in February for US$549.
NVIDIA also unveiled Project Digits, a desktop PC designed to empower AI researchers, data scientists and students; it has the ability to run very large AI models on laptops. Developed in collaboration with Taiwan's MediaTek (TPE:2454), the model is equipped with a Grace Blackwell Superchip and runs a version of the Linux operating system. Project Digits essentially puts an AI-powered personal supercomputer within reach for US$3,000 starting in May.
NVIDIA performance, January 6 to 10, 2025.
Chart via Google Finance.
NVIDIA's move highlights a broader trend at CES this year: the rise of AI PCs. AMD, Intel (NASDAQ:INTC) and Qualcomm (NASDAQ:QCOM) all introduced chips designed to bring AI to everyday computing. AMD's high-powered Ryzen CPUs, which will power Dell’s (NYSE:DELL) corporate PCs, reportedly outperform Macs and offer a longer battery life.
Meanwhile, Qualcomm is broadening its business beyond mobile phone chips with the Snapdragon X Platform, an affordable chip for laptops and PCs that will run Microsoft’s (NASDAQ:MSFT) Copilot+ software. The company will also soon release a small desktop computer built with the chip. PC makers including Dell — which announced a rebranding of its PC line — will reportedly offer laptops based on the new product in early 2025.
AMD, Qualcomm and Dell saw share price increases of between 2 and 3.5 percent between Monday and Tuesday. However, Intel’s new processors featuring built-in AI acceleration and a dedicated neural-processing unit in select models weren’t enough to impress investors, and its share price was little changed over the same period.
2. Autonomous vehicles have their moment
While AI PCs generated excitement at CES, another trend emerged: the rise of generative physical AI.
During his keynote, Huang emphasized how this forthcoming shift will revolutionize factory and warehouse automation, a rising subsector he described as "a multi-trillion dollar opportunity."
This sentiment is seemingly shared by OpenAI founder Sam Altman, who wrote in a weekend blog post of a near future where “AI agents join the workforce and materially change the output of companies."
To accelerate this transition, Huang unveiled NVIDIA Cosmos, an open-source platform designed to simulate real-world environments and accelerate the training of physical AI models like robots and cars. Within Cosmos, AI agents can be trained using Nemotron, a new family of large language models optimized for agentic AI. Based on Meta's (NASDAQ:META) Llama models, Nemotron leverages NVIDIA's CUDA and AI acceleration technologies.
“Cosmos will dramatically accelerate the time to train intelligent robots and advanced self-driving cars,” Rev Lebaredian, vice president of omniverse and simulation technology at NVIDIA, said at a press conference on Monday.
Later, news broke of a partnership between NVIDIA and Toyota (NYSE:TM) that will see the carmaker use NVIDIA's autonomous driving chips and software to advance its self-driving cars. NVIDIA also announced a partnership with Uber (NYSE:UBER) to use its drive logs for AI model training.
“After so many years, with Waymo and Tesla's (NASDAQ:TSLA) success, it's very clear (autonomous vehicles) have finally arrived,” said Huang on Monday. Later, during an interview with Yahoo Finance’s Dan Howley, he disclosed that NVIDIA's technology for autonomous driving is projected to generate US$5 billion in annual sales.
3. Bitcoin price falls below US$100,000
The Bitcoin price rose above US$102,000 early on Monday, following a weekend in which the cryptocurrency regained its 50 day simple moving average, an indicator often described as crucial for a continued bull market.
Adding to the momentum was strong speculation that MicroStrategy (NASDAQ:MSTR) was preparing to increase its holdings further after CEO Michael Saylor hinted at a potential acquisition over the weekend.
The company ultimately purchased 1,070 Bitcoins for a total price of US$101 million.
Adding to bullish sentiment was a research report from JPMorgan (NYSE:JPM); it indicates that Bitcoin miners' revenue increased for the second consecutive month in December. The positivity extended to altcoins as Solana’s DEX trading volume exceeded that of Ethereum and Base; the price action prompted analysts to set a US$15 target for XRP.
However, as conflicting US jobs and inflation data rolled in, traders' hopes of an interest rate cut by March diminished. Yields for 10 year Treasuries touched 4.73 percent, resulting in a broad selloff affecting cryptocurrencies and other risk-on assets like tech stocks. The top cryptocurrencies dropped between 4 and 9 percent in early trading on Tuesday.
Bitcoin performance, January 6 to 10, 2025.
Chart via CoinGecko.
US Bitcoin exchange-traded funds (ETFs) saw near-record outflows of US$582 million on Wednesday (January 8) as the downward trajectory continued. Ether ETFs saw substantial outflows totaling US$159.3 million on Wednesday, their largest on record since July. By Thursday (January 9), US$655 million in Bitcoin futures contracts had been liquidated.
Adding to the uncertainty, the US Department of Justice has reportedly been cleared to sell US$6.5 billion worth of Bitcoin seized from Silk Road, which could put downward pressure on Bitcoin’s price.
Altcoins saw greater losses, with XRP being the sole exception.
Ripple’s native cryptocurrency saw periods of recovery on Wednesday after it was reported that CEO Brad Garlinghouse and Chief Legal Officer Stuart Alderoty met with Trump for dinner. Analysts at Cointelegraph project XRP could surge 40 percent if prices can break out of the current “descending triangle” pattern.
Friday’s (January 10) US jobs data release coincided with a 2.24 percent drop in Bitcoin’s price to below US$92,000 before the markets opened, followed by a rise to US$95,000 midday. Bitcoin’s latest downtrend has led market analysts to believe that the coin's price may retest areas around US$90,000 as traders contend with uncertainty regarding tariffs and their effects on the US economy, stoking concerns about the possibility of renewed inflation.
According to Santiment analyst Brianq, Bitcoin's performance can also be partly attributed to decreased purchasing activity by wallets holding between 100 and 1,000 Bitcoin, which drove Bitcoin’s most recent bull cycle.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Zero Candida Technologies Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects